Insights about U.S. Stocks that landed in the Red-Zone during Tuesday’s trade, are depicted underneath:

CollabRx Inc (NASDAQ:CLRX)’s shares dwindled -5.71%, and closed at $1.32, during the last trading session.

CollabRx, Inc. (CLRX), declared the closing of its formerly declared underwritten public offering of 2,362,205 shares of its ordinary stock at an offering price of $1.27 per ordinary share. In addition, the underwriter exercised the over-allotment option to purchase an additional 354,330 shares. Gross proceeds to CollabRx from this offering are about $3,450,000 before deducting underwriting

Aegis Capital Corp. acted as the sole book-running manager for the offering.

CollabRx, Inc. is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.

Stage Stores Inc (NYSE:SSI), declined -5.65%, and closed at $19.55.

Stage Stores Inc. (SSI), stated financial results for the fourth quarter and fiscal year ended January 31, 2015.

Fourth Quarter Stated Results:

Sales raised 6.6% to $524.9 million contrast to $492.5 million in the preceding year period. Comparable sales raised 6.4%. Three stores opened and four stores closed during the quarter. Net revenue from ongoing operations was $43.8 million or $1.36 per diluted share.

Full Year Stated Results:

Sales raised 1.8% to $1,639 million contrast to $1,609 million in the preceding year period. Comparable sales raised 1.4%. Eighteen stores opened and twelve stores closed during the year. Net revenue from ongoing operations was $37.9 million or $1.18 per diluted share.

Stage Stores, Inc. operates as a specialty department store retailer in the United States. The corporation operates its stores under the nameplates of Bealls, Goody’s, Palais Royal, Peebles, and Stage.

Arena Pharmaceuticals, Inc (NASDAQ:ARNA) dipped -5.61%, and closed at $4.04.

Arena Pharmaceuticals, Inc. (ARNA), offered a corporate update and stated financial results for the fourth quarter and full year ended December 31, 2014.

Arena Research & Development:

• Declared top-line results from a Phase 1b multiple-ascending dose clinical trial for APD334, an oral drug modulator of the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases.
• Initiated patient dosing in a Phase 2 clinical trial of ralinepag, an oral, non-prostanoid prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension.
• Arena and Eisai declared top-line results of a pilot study to assess the safety of lorcaserin when co-administered with phentermine.
• Arena and Eisai declared top-line results from the Phase 2 clinical trial investigating lorcaserin for smoking cessation.

Arena Pharmaceuticals, Inc., a biopharmaceutical corporation, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The corporation offers BELVIQ, a drug used to treat chronic weight administration in adults.

Gastar Exploration Inc (NYSEMKT:GST), dropped -5.12 %, and closed at $2.78.

Gastar Exploration Inc. (GST), declared that it has declared monthly cash dividends on its 8.625% Series A Preferred Stock and its 10.75% Series B Preferred Stock for March 2015.

The dividend on the Series A Preferred Stock is payable on March 31, 2015 to holders of record at the close of business on March 13, 2015. The March 2015 dividend payment will be an annualized 8.625% per share, which is equivalent to $0.179688 per share, based on the $25.00 per share liquidation preference of the Series A Preferred Stock. The Series A Preferred Stock is presently listed on the NYSE MKT and trades under the ticker symbol “GST.PRA.”

The dividend on the Series B Preferred Stock is payable on March 31, 2015 to holders of record at the close of business on March 13, 2015. The March 2015 dividend payment will be an annualized 10.75% per share, which is equivalent to $0.223958 per share, based on the $25.00 per share liquidation preference of the Series B Preferred Stock. The Series B Preferred Stock is presently listed on the NYSE MKT and trades under the ticker symbol “GST.PRB.”

Gastar Exploration Inc., an independent energy corporation, is engaged in the exploration, development, and production of oil, condensate, natural gas, and natural gas liquids in the United States.